SIMILAR PATTERNS OF AMINO ACIDS FOR 2ITO_A_IREA2020

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 220 LYS A 222 GLU A 236 MET A 240 THR A 266 GLY A 272 LEU A 321	None	0.73A	2itoA-1k9aA: 32.2	2itoA-1k9aA: 25.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 220 LYS A 222 GLU A 236 THR A 266 GLY A 272 ASP A 276 LEU A 321	None	0.76A	2itoA-1k9aA: 32.2	2itoA-1k9aA: 25.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A)	0.81A	2itoA-1opkA: 30.3	2itoA-1opkA: 25.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 ALA A 288 LYS A 290 GLU A 305 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.83A	2itoA-1opkA: 30.3	2itoA-1opkA: 25.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	ALA A 230 LYS A 232 GLU A 245 LEU A 278 GLY A 286 ASP A 290 LEU A 340	PY1 A 700 (-3.5A) PY1 A 700 (-3.9A) PY1 A 700 ( 4.9A) PY1 A 700 (-3.8A) PY1 A 700 (-3.6A) None PY1 A 700 (-4.4A)	0.74A	2itoA-1py5A: 26.8	2itoA-1py5A: 25.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 389 LYS A 391 LEU A 433 GLY A 441 ASP A 445 LEU A 489	None	0.63A	2itoA-1snxA: 29.8	2itoA-1snxA: 32.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 ALA A 621 LYS A 623 GLU A 640 THR A 670 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.6A) STI A 3 (-3.2A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.74A	2itoA-1t46A: 24.9	2itoA-1t46A: 31.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 ALA A 36 LYS A 38 GLU A 55 LEU A 82 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) None None None HYM A 400 (-4.5A)	0.70A	2itoA-1zltA: 22.4	2itoA-1zltA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 ALA X 37 GLU X 54 THR X 82 GLY X 88 ASP X 92 LEU X 137	STU X 902 (-3.8A) STU X 902 (-3.1A) STU X 902 ( 4.4A) STU X 902 (-4.1A) STU X 902 (-3.5A) None STU X 902 (-4.4A)	0.75A	2itoA-2dq7X: 31.9	2itoA-2dq7X: 32.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU X 17 ALA X 37 LYS X 39 GLU X 54 MET X 58 THR X 82 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 ( 4.4A) None STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.77A	2itoA-2dq7X: 31.9	2itoA-2dq7X: 32.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 ALA A 293 LYS A 295 THR A 338 GLY A 344 ASP A 348 LEU A 393	H8H A 534 (-3.8A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) H8H A 534 (-3.1A) H8H A 534 (-3.3A) None H8H A 534 (-4.5A)	0.56A	2itoA-2h8hA: 29.3	2itoA-2h8hA: 22.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LYS A 295 THR A 338 GLY A 344 ASP A 348 LEU A 393	QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 ( 4.1A) QUE A 1 (-4.4A)	0.71A	2itoA-2hckA: 28.4	2itoA-2hckA: 25.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 ALA A 293 LYS A 295 THR A 338 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.70A	2itoA-2hckA: 28.4	2itoA-2hckA: 25.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 251 ALA A 271 LYS A 273 GLU A 288 MET A 292 THR A 316 GLY A 322 ASP A 326 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) 1BM A 499 (-3.2A) 1BM A 499 ( 3.8A) 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) None 1BM A 499 (-4.4A)	0.68A	2itoA-2hk5A: 32.2	2itoA-2hk5A: 33.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 55 ALA A 76 LYS A 78 LEU A 122 GLY A 130 LEU A 177	None	0.69A	2itoA-2hw6A: 20.6	2itoA-2hw6A: 22.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 ALA A 269 LYS A 271 GLU A 286 MET A 290 THR A 315 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A)	0.86A	2itoA-2hz0A: 30.7	2itoA-2hz0A: 36.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 248 ALA A 269 THR A 315 GLY A 321 ASP A 325 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 (-3.1A) GIN A 600 (-3.4A) None None GIN A 600 (-4.7A)	0.69A	2itoA-2hz0A: 30.7	2itoA-2hz0A: 36.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 251 ALA A 271 LYS A 273 GLU A 288 MET A 292 THR A 316 GLY A 322 ASP A 326 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.5A) None 1N8 A 501 ( 4.3A)	0.93A	2itoA-2og8A: 29.8	2itoA-2og8A: 33.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	8	LEU A 25 ALA A 46 LYS A 48 LEU A 101 GLY A 109 ASP A 113 LEU A 156 THR A 166	ATP A 381 ( 4.3A) ATP A 381 (-3.5A) ATP A 381 (-3.2A) None None None ATP A 381 ( 4.8A) ATP A 381 ( 4.6A)	0.83A	2itoA-2phkA: 23.6	2itoA-2phkA: 25.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 ALA A 515 LYS A 517 GLU A 534 MET A 538 GLY A 570 LEU A 633	None	0.99A	2itoA-2psqA: 33.6	2itoA-2psqA: 31.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	ALA B 67 LYS B 69 GLU B 85 LEU B 112 GLY B 120 LEU B 171	None	0.74A	2itoA-2qkwB: 25.3	2itoA-2qkwB: 26.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 215 LYS A 217 GLU A 230 LEU A 263 GLY A 271 ASP A 275 LEU A 328	ADE A 488 (-3.2A) None None None ADE A 488 ( 4.1A) None ADE A 488 (-4.4A)	0.73A	2itoA-2qluA: 25.8	2itoA-2qluA: 25.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 215 LYS A 217 THR A 265 GLY A 271 ASP A 275 LEU A 328	ADE A 488 (-3.2A) None ADE A 488 (-4.3A) ADE A 488 ( 4.1A) None ADE A 488 (-4.4A)	0.52A	2itoA-2qluA: 25.8	2itoA-2qluA: 25.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 705 GLU A 724 MET A 728 THR A 753 GLY A 759 LEU A 807	None	0.70A	2itoA-2r2pA: 34.0	2itoA-2r2pA: 33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 724 ALA A 749 LYS A 751 LEU A 794 THR A 796 GLY A 802 LEU A 850 THR A 860	GW7 A 1 ( 4.2A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.1A) GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A)	0.66A	2itoA-2r4bA: 30.1	2itoA-2r4bA: 78.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 226 ALA A 247 LYS A 249 GLY A 307 ASP A 311 LEU A 354 THR A 367	XK9 A1511 (-3.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.2A) XK9 A1511 ( 3.7A) None XK9 A1511 (-4.6A) XK9 A1511 (-3.7A)	0.81A	2itoA-2xk9A: 15.3	2itoA-2xk9A: 27.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	ALA A 651 LYS A 653 MET A 674 THR A 699 GLY A 705 LEU A 753	Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 (-3.9A) Q9G A1898 (-3.5A) Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.72A	2itoA-2xyuA: 26.5	2itoA-2xyuA: 36.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 51 LYS A 53 LEU A 105 GLY A 113 ASP A 117 LEU A 160	B49 A1294 (-3.2A) None None B49 A1294 (-3.6A) None B49 A1294 (-4.4A)	0.66A	2itoA-2y7jA: 24.6	2itoA-2y7jA: 21.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1002 ALA A1028 LYS A1030 GLU A1047 MET A1051 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None S91 A 1 (-3.3A)	0.70A	2itoA-2z8cA: 30.5	2itoA-2z8cA: 32.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 253 ALA A 273 LYS A 275 GLU A 290 MET A 294 GLY A 325 ASP A 329 LEU A 374	None	0.77A	2itoA-2zv7A: 32.8	2itoA-2zv7A: 33.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 253 ALA A 273 LYS A 275 MET A 294 THR A 319 GLY A 325 ASP A 329 LEU A 374	None	0.76A	2itoA-2zv7A: 32.8	2itoA-2zv7A: 33.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 ALA A 515 LYS A 517 GLU A 534 MET A 538 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 (-3.3A) M33 A1996 ( 4.5A) None None M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.97A	2itoA-3b2tA: 33.1	2itoA-3b2tA: 31.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 220 LYS A 222 GLU A 236 MET A 240 THR A 266 GLY A 272 LEU A 321	None	0.73A	2itoA-3d7uA: 27.4	2itoA-3d7uA: 35.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 220 LYS A 222 GLU A 236 THR A 266 GLY A 272 ASP A 276 LEU A 321	None	0.76A	2itoA-3d7uA: 27.4	2itoA-3d7uA: 35.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3g2f	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 228 LYS A 230 GLU A 243 LEU A 277 GLY A 285 LEU A 340	ADP A 900 (-3.4A) ADP A 900 (-2.8A) ADP A 900 ( 4.7A) None ADP A 900 ( 4.2A) ADP A 900 (-4.6A)	0.68A	2itoA-3g2fA: 26.1	2itoA-3g2fA: 25.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 696 LYS A 723 LEU A 766 THR A 768 GLY A 774 ASP A 778 LEU A 822	ANP A 1 (-4.4A) ANP A 1 (-3.4A) None ANP A 1 ( 4.8A) ANP A 1 ( 4.9A) None ANP A 1 (-4.7A)	0.57A	2itoA-3kexA: 31.7	2itoA-3kexA: 54.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ALA A 665 LYS A 667 GLU A 684 MET A 688 THR A 713 GLY A 719 LEU A 767	None None None None None GOL A 403 (-3.4A) None	0.80A	2itoA-3kulA: 34.1	2itoA-3kulA: 32.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 694 ALA A 719 LEU A 764 THR A 766 GLY A 772 ASP A 776 LEU A 820 THR A 830	ITI A 1 (-3.9A) ITI A 1 (-2.9A) ITI A 1 ( 4.2A) ITI A 1 (-3.8A) ITI A 1 (-3.5A) None ITI A 1 (-4.6A) ITI A 1 (-3.8A)	0.89A	2itoA-3lzbA: 34.0	2itoA-3lzbA: 87.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 192 ALA A 213 LYS A 215 GLU A 234 LEU A 261 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None None None AMP A 577 (-4.8A)	0.54A	2itoA-3nyoA: 23.6	2itoA-3nyoA: 22.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 726 ALA A 751 LYS A 753 LEU A 796 THR A 798 GLY A 804 ASP A 808 LEU A 852 THR A 862	03Q A 1 (-3.8A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 (-4.3A) 03Q A 1 (-4.1A) 03Q A 1 ( 3.9A) None 03Q A 1 (-4.4A) 03Q A 1 (-3.3A)	0.71A	2itoA-3pp0A: 36.9	2itoA-3pp0A: 78.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 217 LYS A 219 GLU A 232 LEU A 265 GLY A 273 LEU A 329	TAK A 2 (-3.5A) TAK A 2 (-2.9A) TAK A 2 ( 4.9A) None TAK A 2 (-3.6A) TAK A 2 (-4.6A)	0.73A	2itoA-3q4tA: 25.6	2itoA-3q4tA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 63 ALA A 84 LYS A 86 GLU A 115 LEU A 142 THR A 144	ANP A1634 ( 4.3A) ANP A1634 (-3.6A) ANP A1634 (-3.1A) None None ANP A1634 (-4.6A)	0.73A	2itoA-3q5iA: 23.1	2itoA-3q5iA: 22.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.99A	2itoA-3s95A: 27.1	2itoA-3s95A: 27.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 423 ALA A 443 LYS A 445 THR A 489 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) PP2 A 1 (-3.3A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.64A	2itoA-3sxsA: 30.8	2itoA-3sxsA: 30.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 423 ALA A 443 MET A 464 THR A 489 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) PP2 A 1 (-3.3A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.75A	2itoA-3sxsA: 30.8	2itoA-3sxsA: 30.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1951 ALA A1978 LYS A1980 MET A2001 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.74A	2itoA-3zbfA: 26.1	2itoA-3zbfA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 649 LYS A 651 GLU A 668 MET A 672 THR A 697 GLY A 703 LEU A 751	None	0.80A	2itoA-3zfxA: 34.7	2itoA-3zfxA: 36.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 ALA A 104 LYS A 106 LEU A 152 GLY A 160 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 (-3.4A) VX6 A 500 (-3.3A) None VX6 A 500 (-3.3A) VX6 A 500 (-4.6A)	0.72A	2itoA-4af3A: 19.7	2itoA-4af3A: 23.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 840 ALA A 866 LYS A 868 GLU A 885 GLY A 922 LEU A1035	B49 A2000 (-3.7A) B49 A2000 (-3.5A) B49 A2000 (-3.0A) None B49 A2000 ( 3.7A) B49 A2000 (-4.5A)	0.74A	2itoA-4agdA: 29.9	2itoA-4agdA: 30.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 121 LYS A 123 MET A 144 THR A 169 GLY A 175 LEU A 223	30K A1365 (-3.2A) 30K A1365 (-3.8A) None 30K A1365 (-3.8A) 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.72A	2itoA-4aw5A: 32.7	2itoA-4aw5A: 33.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	ALA A 233 LYS A 235 GLU A 248 LEU A 281 GLY A 289 ASP A 293 LEU A 343	TAK A1507 (-3.3A) TAK A1507 ( 4.5A) None None TAK A1507 (-3.5A) None TAK A1507 (-4.7A)	0.92A	2itoA-4c02A: 26.9	2itoA-4c02A: 23.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	ALA A 233 LYS A 235 GLU A 248 THR A 283 GLY A 289 ASP A 293 LEU A 343	TAK A1507 (-3.3A) TAK A1507 ( 4.5A) None TAK A1507 (-3.6A) TAK A1507 (-3.5A) None TAK A1507 (-4.7A)	0.91A	2itoA-4c02A: 26.9	2itoA-4c02A: 23.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 ALA A 653 LYS A 655 GLU A 672 MET A 676 THR A 701	None DI1 A1000 (-3.6A) DI1 A1000 (-3.9A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.6A)	0.71A	2itoA-4ckrA: 29.3	2itoA-4ckrA: 32.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 377 ALA A 400 LYS A 402 GLU A 420 MET A 424 LEU A 446 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None None None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.65A	2itoA-4f4pA: 32.5	2itoA-4f4pA: 39.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 377 ALA A 400 LYS A 402 LEU A 446 GLY A 454 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) None ANP A 701 ( 4.2A) ANP A 701 (-4.5A)	0.43A	2itoA-4fl3A: 29.7	2itoA-4fl3A: 25.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 855 ALA A 880 LYS A 882 GLU A 898 LEU A 927 GLY A 935 ASP A 939 LEU A 983	IZA A2001 (-3.7A) IZA A2001 (-3.4A) IZA A2001 ( 4.7A) None None IZA A2001 (-3.3A) None IZA A2001 ( 4.7A)	0.80A	2itoA-4gl9A: 30.9	2itoA-4gl9A: 34.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 828 ALA A 853 LYS A 855 GLU A 871 LEU A 900 GLY A 908 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-3.3A) 19S A1201 (-3.5A) None None 19S A1201 ( 3.8A) 19S A1201 (-4.5A)	0.91A	2itoA-4hviA: 31.9	2itoA-4hviA: 34.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	LEU A 132 ALA A 156 LYS A 158 THR A 205 GLY A 211 ASP A 215 LEU A 259	None	0.63A	2itoA-4hzsA: 29.3	2itoA-4hzsA: 36.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 132 ALA A 156 LYS A 158 THR A 205 GLY A 211 ASP A 215 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) None 1G0 A 401 (-4.6A)	0.77A	2itoA-4id7A: 32.5	2itoA-4id7A: 36.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 ALA A 293 LYS A 295 GLY A 344 ASP A 348 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) 0J9 A 601 ( 4.1A) None 0J9 A 601 (-4.5A)	0.50A	2itoA-4k11A: 29.0	2itoA-4k11A: 26.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 478 ALA A 506 LYS A 508 GLU A 525 MET A 529 GLY A 561 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-3.3A) ACP A 801 (-2.7A) ACP A 801 ( 4.8A) None ACP A 801 ( 4.6A) ACP A 801 (-4.4A)	0.71A	2itoA-4k33A: 26.9	2itoA-4k33A: 32.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 434 LYS A 436 MET A 456 GLY A 487 ASP A 491 LEU A 533	B49 A 701 (-3.2A) None None B49 A 701 ( 3.7A) B49 A 701 ( 4.3A) B49 A 701 (-4.5A)	0.68A	2itoA-4ks8A: 25.1	2itoA-4ks8A: 26.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 33 ALA A 54 LYS A 56 MET A 74 GLY A 105 LEU A 153	GOL A 404 ( 3.6A) GOL A 404 ( 3.1A) GOL A 403 ( 4.6A) None GOL A 404 (-3.6A) GOL A 403 ( 4.4A)	0.71A	2itoA-4lg4A: 17.6	2itoA-4lg4A: 28.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	LEU A 273 ALA A 293 LYS A 295 GLU A 310 MET A 314 GLY A 344 ASP A 348	VGG A 601 (-3.2A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.3A) VGG A 601 ( 3.6A) VGG A 601 ( 3.2A) None	0.90A	2itoA-4lggA: 29.6	2itoA-4lggA: 32.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	LEU A 273 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 LEU A 393	VGG A 601 (-3.2A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 3.6A) VGG A 601 ( 3.2A) None VGG A 601 (-4.5A)	0.61A	2itoA-4lggA: 29.6	2itoA-4lggA: 32.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	ALA A 49 LYS A 51 LEU A 93 THR A 95 GLY A 101 LEU A 150	ANP A 401 (-3.1A) ANP A 401 (-2.9A) None ANP A 401 (-3.8A) None ANP A 401 (-4.8A)	0.69A	2itoA-4m69A: 24.0	2itoA-4m69A: 25.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 ALA A 67 LYS A 69 GLU A 85 LEU A 121 THR A 123 GLY A 128 LEU A 180	SIN A 401 ( 3.9A) SIN A 401 ( 3.7A) None None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.68A	2itoA-4o38A: 21.0	2itoA-4o38A: 22.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 ALA A 67 LYS A 69 GLU A 85 MET A 89 LEU A 121 THR A 123 GLY A 128	SIN A 401 ( 3.9A) SIN A 401 ( 3.7A) None None None None None SIN A 401 (-3.5A)	0.77A	2itoA-4o38A: 21.0	2itoA-4o38A: 22.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 ALA A 928 GLU A 947 LEU A 976 GLY A 984 ASP A 988 LEU A1030	2TT A1202 (-3.5A) 2TT A1202 ( 3.9A) None None 2TT A1202 (-3.4A) None 2TT A1202 (-4.4A)	0.93A	2itoA-4oliA: 29.5	2itoA-4oliA: 20.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 818	P30 A1001 (-3.8A) P30 A1001 (-3.4A) P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.70A	2itoA-4rt7A: 24.7	2itoA-4rt7A: 28.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 ALA A 642 LYS A 644 GLU A 661 LEU A 689 GLY A 697	P30 A1001 (-3.8A) P30 A1001 (-3.4A) P30 A1001 (-3.4A) P30 A1001 (-3.6A) None P30 A1001 (-3.4A)	0.73A	2itoA-4rt7A: 24.7	2itoA-4rt7A: 28.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	LEU A 14 ALA A 35 LYS A 37 GLU A 52 MET A 56 GLY A 87 ASP A 91 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-2.9A) None None None ACP A1264 (-3.5A) None ACP A1264 ( 4.8A)	0.78A	2itoA-4ueuA: 32.3	2itoA-4ueuA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	LEU A 14 ALA A 35 LYS A 37 MET A 56 THR A 81 GLY A 87 ASP A 91 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-2.9A) None None ACP A1264 (-4.5A) ACP A1264 (-3.5A) None ACP A1264 ( 4.8A)	0.74A	2itoA-4ueuA: 32.3	2itoA-4ueuA: 35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 ALA A 214 LYS A 216 GLU A 235 LEU A 262 GLY A 270 LEU A 321	ANW A 601 ( 4.0A) ANW A 601 (-3.4A) None None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.68A	2itoA-4wboA: 24.3	2itoA-4wboA: 20.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.67A	2itoA-4xeyB: 26.8	2itoA-4xeyB: 28.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	7	LEU B 267 ALA B 288 LYS B 290 THR B 334 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.63A	2itoA-4xeyB: 26.8	2itoA-4xeyB: 28.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 ALA A 642 GLU A 661 LEU A 689 GLY A 697 LEU A 818	P30 A1001 (-4.0A) P30 A1001 (-3.5A) P30 A1001 (-3.1A) None P30 A1001 (-3.5A) P30 A1001 (-4.3A)	0.63A	2itoA-4xufA: 24.1	2itoA-4xufA: 32.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 ALA A 214 LYS A 216 GLU A 235 LEU A 262 LEU A 319	AN2 A 601 ( 4.2A) AN2 A 601 (-3.6A) AN2 A 601 ( 3.9A) None None None	0.68A	2itoA-4yhjA: 22.7	2itoA-4yhjA: 21.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	8	LEU A 34 ALA A 55 LYS A 57 GLU A 76 LEU A 103 THR A 105 GLY A 111 LEU A 158	ADP A 506 ( 3.8A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) None None ADP A 506 ( 4.6A) None ADP A 506 (-4.7A)	1.00A	2itoA-4ysjA: 24.4	2itoA-4ysjA: 22.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	LEU A 34 ALA A 55 LYS A 57 THR A 105 GLY A 111 ASP A 115 LEU A 158	ADP A 506 ( 3.8A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) ADP A 506 ( 4.6A) None None ADP A 506 (-4.7A)	1.00A	2itoA-4ysjA: 24.4	2itoA-4ysjA: 22.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 ALA A 512 LYS A 514 GLU A 531 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) EDO A1766 (-4.1A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.67A	2itoA-5a46A: 30.9	2itoA-5a46A: 31.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 44 LYS A 46 GLU A 63 LEU A 90 GLY A 98 LEU A 145	51W A 401 (-3.4A) GOL A 404 ( 3.1A) None None 51W A 401 (-3.7A) 51W A 401 (-4.5A)	0.73A	2itoA-5ci7A: 19.1	2itoA-5ci7A: 26.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 275 LYS A 277 GLU A 290 LEU A 323 THR A 325 GLY A 331 LEU A 386	STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 ( 3.8A) None STU A 601 ( 3.7A) STU A 601 (-3.5A) STU A 601 (-3.9A)	0.52A	2itoA-5e8yA: 25.9	2itoA-5e8yA: 25.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	6	LEU A 99 ALA A 120 LYS A 122 LEU A 168 GLY A 176 LEU A 223	5U5 A 401 (-3.8A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) None 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A)	0.53A	2itoA-5eykA: 24.8	2itoA-5eykA: 23.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 903 ALA A 928 LYS A 930 GLU A 947 LEU A 976 GLY A 984 ASP A 988 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 (-3.5A) None None None 5U3 A1200 (-3.2A) None 5U3 A1200 (-4.4A)	0.87A	2itoA-5f1zA: 29.8	2itoA-5f1zA: 30.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 730 ALA A 756 LYS A 758 LEU A 802 GLY A 810 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) None PTR A 809 (-2.4A) PP1 A2012 (-4.6A)	0.47A	2itoA-5fm2A: 33.4	2itoA-5fm2A: 30.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 599 ALA A 625 LYS A 627 GLU A 644 MET A 648 THR A 674	748 A1001 (-3.8A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 (-3.2A)	0.75A	2itoA-5grnA: 24.9	2itoA-5grnA: 30.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 599 ALA A 625 LYS A 627 GLU A 644 THR A 674 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.3A) 748 A1001 (-3.2A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.70A	2itoA-5grnA: 24.9	2itoA-5grnA: 30.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	LEU A 20 ALA A 41 LYS A 43 GLU A 61 LEU A 88 GLY A 96 LEU A 143	ADP A 301 ( 4.0A) ADP A 301 (-3.5A) ADP A 301 (-2.7A) None None None ADP A 301 (-4.7A)	0.87A	2itoA-5hu3A: 24.9	2itoA-5hu3A: 23.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 718 ALA A 743 LYS A 745 GLU A 762 MET A 766 LEU A 788 GLY A 796 ASP A 800 LEU A 844 THR A 854	6HJ A1101 ( 4.6A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) 6HJ A1101 ( 4.2A) 6HJ A1101 ( 4.1A) 6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.1A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A)	0.54A	2itoA-5j9zA: 44.0	2itoA-5j9zA: 99.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 417 LYS A 419 GLU A 436 LEU A 463 GLY A 471 ASP A 475 LEU A 518	GUI A 701 ( 3.9A) GUI A 701 (-3.1A) None None GUI A 701 (-3.6A) GUI A 701 (-4.1A) GUI A 701 (-4.4A)	0.73A	2itoA-5jznA: 24.0	2itoA-5jznA: 25.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	6	SER A 42 ALA A 60 LEU A 108 GLY A 116 LEU A 163 THR A 173	STU A 901 ( 4.8A) STU A 901 (-3.3A) None STU A 901 (-3.5A) STU A 901 (-4.5A) STU A 901 (-3.5A)	0.67A	2itoA-5lohA: 20.3	2itoA-5lohA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ALA A 909 LYS A 911 GLU A 927 LEU A 954 GLY A 962 LEU A1016	ATP A1200 (-3.5A) ATP A1200 (-3.8A) None None ATP A1200 ( 4.0A) ATP A1200 (-4.6A)	0.51A	2itoA-5lpyA: 24.8	2itoA-5lpyA: 27.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	ALA A 909 LYS A 911 GLU A 927 LEU A 954 GLY A 962 ASP A 966 LEU A1016	ADP A1200 (-3.5A) ADP A1200 ( 4.3A) None None ADP A1200 ( 4.0A) ADP A1200 (-4.2A) ADP A1200 (-4.7A)	0.69A	2itoA-5lpzA: 24.7	2itoA-5lpzA: 26.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 119 LYS A 121 GLU A 140 MET A 144 GLY A 175 LEU A 221	None	0.73A	2itoA-5u7qA: 21.4	2itoA-5u7qA: 24.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	7	LEU A 24 SER A 25 ALA A 45 LYS A 47 THR A 95 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) None 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.76A	2itoA-5w5jA: 23.2	2itoA-5w5jA: 28.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wnm	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 4 (Mus musculus)	no annotation	6	ALA A 49 GLU A 69 MET A 73 LEU A 94 GLY A 102 LEU A 150	VX6 A 402 (-3.2A) VX6 A 402 (-4.4A) None None VX6 A 402 (-3.5A) VX6 A 402 (-4.4A)	0.71A	2itoA-5wnmA: 28.5	2itoA-5wnmA: 13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	LEU A 891 ALA A 917 LYS A 919 THR A 963 GLY A 969 LEU A1017 THR A1027	ANP A1201 (-4.1A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) ANP A1201 (-3.9A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A) ANP A1201 ( 4.9A)	0.77A	2itoA-5wnoA: 31.4	2itoA-5wnoA: 12.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 ALA A 906 LYS A 908 GLU A 925 LEU A 954 GLY A 962 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-3.4A) ADP A1201 (-2.8A) None None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.79A	2itoA-6c7yA: 31.1	2itoA-6c7yA: 14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	6	LEU A 730 ALA A 756 GLU A 775 LEU A 802 GLY A 810 LEU A 881	ADN A1104 ( 4.0A) ADN A1104 (-3.4A) None None ADN A1104 ( 3.8A) ADN A1104 (-4.3A)	0.69A	2itoA-6fekA: 32.2	2itoA-6fekA: 14.29

[["2ITO_A_IREA2020_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 220;LYS A 222;GLU A 236;MET A 240;THR A 266;GLY A 272;LEU A 321","None","0.73A","2itoA-1k9aA:32.2","2itoA-1k9aA:25.97"],["2ITO_A_IREA2020_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 220;LYS A 222;GLU A 236;THR A 266;GLY A 272;ASP A 276;LEU A 321","None","0.76A","2itoA-1k9aA:32.2","2itoA-1k9aA:25.97"],["2ITO_A_IREA2020_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A)","0.81A","2itoA-1opkA:30.3","2itoA-1opkA:25.09"],["2ITO_A_IREA2020_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.83A","2itoA-1opkA:30.3","2itoA-1opkA:25.09"],["2ITO_A_IREA2020_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"ALA A 230;LYS A 232;GLU A 245;LEU A 278;GLY A 286;ASP A 290;LEU A 340","PY1 A 700 (-3.5A);PY1 A 700 (-3.9A);PY1 A 700 ( 4.9A);PY1 A 700 (-3.8A);PY1 A 700 (-3.6A);None;PY1 A 700 (-4.4A)","0.74A","2itoA-1py5A:26.8","2itoA-1py5A:25.28"],["2ITO_A_IREA2020_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",6,"ALA A 389;LYS A 391;LEU A 433;GLY A 441;ASP A 445;LEU A 489","None","0.63A","2itoA-1snxA:29.8","2itoA-1snxA:32.41"],["2ITO_A_IREA2020_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"LEU A 595;ALA A 621;LYS A 623;GLU A 640;THR A 670;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.6A);STI A   3 (-3.2A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.74A","2itoA-1t46A:24.9","2itoA-1t46A:31.58"],["2ITO_A_IREA2020_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;ALA A  36;LYS A  38;GLU A  55;LEU A  82;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);None;None;None;HYM A 400 (-4.5A)","0.70A","2itoA-1zltA:22.4","2itoA-1zltA:25.00"],["2ITO_A_IREA2020_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;ALA X  37;GLU X  54;THR X  82;GLY X  88;ASP X  92;LEU X 137","STU X 902 (-3.8A);STU X 902 (-3.1A);STU X 902 ( 4.4A);STU X 902 (-4.1A);STU X 902 (-3.5A);None;STU X 902 (-4.4A)","0.75A","2itoA-2dq7X:31.9","2itoA-2dq7X:32.84"],["2ITO_A_IREA2020_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"LEU X  17;ALA X  37;LYS X  39;GLU X  54;MET X  58;THR X  82;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 ( 4.4A);None;STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.77A","2itoA-2dq7X:31.9","2itoA-2dq7X:32.84"],["2ITO_A_IREA2020_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;ALA A 293;LYS A 295;THR A 338;GLY A 344;ASP A 348;LEU A 393","H8H A 534 (-3.8A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);H8H A 534 (-3.1A);H8H A 534 (-3.3A);None;H8H A 534 (-4.5A)","0.56A","2itoA-2h8hA:29.3","2itoA-2h8hA:22.07"],["2ITO_A_IREA2020_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LYS A 295;THR A 338;GLY A 344;ASP A 348;LEU A 393","QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 ( 4.1A);QUE A   1 (-4.4A)","0.71A","2itoA-2hckA:28.4","2itoA-2hckA:25.66"],["2ITO_A_IREA2020_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;ALA A 293;LYS A 295;THR A 338;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.70A","2itoA-2hckA:28.4","2itoA-2hckA:25.66"],["2ITO_A_IREA2020_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"LEU A 251;ALA A 271;LYS A 273;GLU A 288;MET A 292;THR A 316;GLY A 322;ASP A 326;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);1BM A 499 (-3.2A);1BM A 499 ( 3.8A);1BM A 499 (-3.2A);1BM A 499 (-3.5A);None;1BM A 499 (-4.4A)","0.68A","2itoA-2hk5A:32.2","2itoA-2hk5A:33.13"],["2ITO_A_IREA2020_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  55;ALA A  76;LYS A  78;LEU A 122;GLY A 130;LEU A 177","None","0.69A","2itoA-2hw6A:20.6","2itoA-2hw6A:22.50"],["2ITO_A_IREA2020_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;ALA A 269;LYS A 271;GLU A 286;MET A 290;THR A 315;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A)","0.86A","2itoA-2hz0A:30.7","2itoA-2hz0A:36.18"],["2ITO_A_IREA2020_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 248;ALA A 269;THR A 315;GLY A 321;ASP A 325;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 (-3.1A);GIN A 600 (-3.4A);None;None;GIN A 600 (-4.7A)","0.69A","2itoA-2hz0A:30.7","2itoA-2hz0A:36.18"],["2ITO_A_IREA2020_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",9,"LEU A 251;ALA A 271;LYS A 273;GLU A 288;MET A 292;THR A 316;GLY A 322;ASP A 326;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.5A);None;1N8 A 501 ( 4.3A)","0.93A","2itoA-2og8A:29.8","2itoA-2og8A:33.44"],["2ITO_A_IREA2020_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",8,"LEU A  25;ALA A  46;LYS A  48;LEU A 101;GLY A 109;ASP A 113;LEU A 156;THR A 166","ATP A 381 ( 4.3A);ATP A 381 (-3.5A);ATP A 381 (-3.2A);None;None;None;ATP A 381 ( 4.8A);ATP A 381 ( 4.6A)","0.83A","2itoA-2phkA:23.6","2itoA-2phkA:25.84"],["2ITO_A_IREA2020_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;ALA A 515;LYS A 517;GLU A 534;MET A 538;GLY A 570;LEU A 633","None","0.99A","2itoA-2psqA:33.6","2itoA-2psqA:31.57"],["2ITO_A_IREA2020_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"ALA B  67;LYS B  69;GLU B  85;LEU B 112;GLY B 120;LEU B 171","None","0.74A","2itoA-2qkwB:25.3","2itoA-2qkwB:26.94"],["2ITO_A_IREA2020_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"ALA A 215;LYS A 217;GLU A 230;LEU A 263;GLY A 271;ASP A 275;LEU A 328","ADE A 488 (-3.2A);None;None;None;ADE A 488 ( 4.1A);None;ADE A 488 (-4.4A)","0.73A","2itoA-2qluA:25.8","2itoA-2qluA:25.36"],["2ITO_A_IREA2020_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"ALA A 215;LYS A 217;THR A 265;GLY A 271;ASP A 275;LEU A 328","ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);ADE A 488 ( 4.1A);None;ADE A 488 (-4.4A)","0.52A","2itoA-2qluA:25.8","2itoA-2qluA:25.36"],["2ITO_A_IREA2020_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 705;GLU A 724;MET A 728;THR A 753;GLY A 759;LEU A 807","None","0.70A","2itoA-2r2pA:34.0","2itoA-2r2pA:33.63"],["2ITO_A_IREA2020_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"LEU A 724;ALA A 749;LYS A 751;LEU A 794;THR A 796;GLY A 802;LEU A 850;THR A 860","GW7 A   1 ( 4.2A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.1A);GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A)","0.66A","2itoA-2r4bA:30.1","2itoA-2r4bA:78.74"],["2ITO_A_IREA2020_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"LEU A 226;ALA A 247;LYS A 249;GLY A 307;ASP A 311;LEU A 354;THR A 367","XK9 A1511 (-3.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.2A);XK9 A1511 ( 3.7A);None;XK9 A1511 (-4.6A);XK9 A1511 (-3.7A)","0.81A","2itoA-2xk9A:15.3","2itoA-2xk9A:27.17"],["2ITO_A_IREA2020_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"ALA A 651;LYS A 653;MET A 674;THR A 699;GLY A 705;LEU A 753","Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 (-3.9A);Q9G A1898 (-3.5A);Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.72A","2itoA-2xyuA:26.5","2itoA-2xyuA:36.30"],["2ITO_A_IREA2020_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",6,"ALA A  51;LYS A  53;LEU A 105;GLY A 113;ASP A 117;LEU A 160","B49 A1294 (-3.2A);None;None;B49 A1294 (-3.6A);None;B49 A1294 (-4.4A)","0.66A","2itoA-2y7jA:24.6","2itoA-2y7jA:21.52"],["2ITO_A_IREA2020_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1002;ALA A1028;LYS A1030;GLU A1047;MET A1051;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;S91 A   1 (-3.3A)","0.70A","2itoA-2z8cA:30.5","2itoA-2z8cA:32.07"],["2ITO_A_IREA2020_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"LEU A 253;ALA A 273;LYS A 275;GLU A 290;MET A 294;GLY A 325;ASP A 329;LEU A 374","None","0.77A","2itoA-2zv7A:32.8","2itoA-2zv7A:33.23"],["2ITO_A_IREA2020_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"LEU A 253;ALA A 273;LYS A 275;MET A 294;THR A 319;GLY A 325;ASP A 329;LEU A 374","None","0.76A","2itoA-2zv7A:32.8","2itoA-2zv7A:33.23"],["2ITO_A_IREA2020_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;ALA A 515;LYS A 517;GLU A 534;MET A 538;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 (-3.3A);M33 A1996 ( 4.5A);None;None;M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.97A","2itoA-3b2tA:33.1","2itoA-3b2tA:31.86"],["2ITO_A_IREA2020_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"ALA A 220;LYS A 222;GLU A 236;MET A 240;THR A 266;GLY A 272;LEU A 321","None","0.73A","2itoA-3d7uA:27.4","2itoA-3d7uA:35.35"],["2ITO_A_IREA2020_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"ALA A 220;LYS A 222;GLU A 236;THR A 266;GLY A 272;ASP A 276;LEU A 321","None","0.76A","2itoA-3d7uA:27.4","2itoA-3d7uA:35.35"],["2ITO_A_IREA2020_1","3g2f","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2","PF00069(Pkinase)",6,"ALA A 228;LYS A 230;GLU A 243;LEU A 277;GLY A 285;LEU A 340","ADP A 900 (-3.4A);ADP A 900 (-2.8A);ADP A 900 ( 4.7A);None;ADP A 900 ( 4.2A);ADP A 900 (-4.6A)","0.68A","2itoA-3g2fA:26.1","2itoA-3g2fA:25.71"],["2ITO_A_IREA2020_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",7,"LEU A 696;LYS A 723;LEU A 766;THR A 768;GLY A 774;ASP A 778;LEU A 822","ANP A   1 (-4.4A);ANP A   1 (-3.4A);None;ANP A   1 ( 4.8A);ANP A   1 ( 4.9A);None;ANP A   1 (-4.7A)","0.57A","2itoA-3kexA:31.7","2itoA-3kexA:54.74"],["2ITO_A_IREA2020_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ALA A 665;LYS A 667;GLU A 684;MET A 688;THR A 713;GLY A 719;LEU A 767","None;None;None;None;None;GOL A 403 (-3.4A);None","0.80A","2itoA-3kulA:34.1","2itoA-3kulA:32.27"],["2ITO_A_IREA2020_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 694;ALA A 719;LEU A 764;THR A 766;GLY A 772;ASP A 776;LEU A 820;THR A 830","ITI A   1 (-3.9A);ITI A   1 (-2.9A);ITI A   1 ( 4.2A);ITI A   1 (-3.8A);ITI A   1 (-3.5A);None;ITI A   1 (-4.6A);ITI A   1 (-3.8A)","0.89A","2itoA-3lzbA:34.0","2itoA-3lzbA:87.46"],["2ITO_A_IREA2020_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 192;ALA A 213;LYS A 215;GLU A 234;LEU A 261;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;None;None;AMP A 577 (-4.8A)","0.54A","2itoA-3nyoA:23.6","2itoA-3nyoA:22.45"],["2ITO_A_IREA2020_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",9,"LEU A 726;ALA A 751;LYS A 753;LEU A 796;THR A 798;GLY A 804;ASP A 808;LEU A 852;THR A 862","03Q A   1 (-3.8A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 (-4.3A);03Q A   1 (-4.1A);03Q A   1 ( 3.9A);None;03Q A   1 (-4.4A);03Q A   1 (-3.3A)","0.71A","2itoA-3pp0A:36.9","2itoA-3pp0A:78.59"],["2ITO_A_IREA2020_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"ALA A 217;LYS A 219;GLU A 232;LEU A 265;GLY A 273;LEU A 329","TAK A   2 (-3.5A);TAK A   2 (-2.9A);TAK A   2 ( 4.9A);None;TAK A   2 (-3.6A);TAK A   2 (-4.6A)","0.73A","2itoA-3q4tA:25.6","2itoA-3q4tA:24.72"],["2ITO_A_IREA2020_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  63;ALA A  84;LYS A  86;GLU A 115;LEU A 142;THR A 144","ANP A1634 ( 4.3A);ANP A1634 (-3.6A);ANP A1634 (-3.1A);None;None;ANP A1634 (-4.6A)","0.73A","2itoA-3q5iA:23.1","2itoA-3q5iA:22.24"],["2ITO_A_IREA2020_1","3s95","Homo sapiens","LIM DOMAIN KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.99A","2itoA-3s95A:27.1","2itoA-3s95A:27.79"],["2ITO_A_IREA2020_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"LEU A 423;ALA A 443;LYS A 445;THR A 489;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);PP2 A   1 (-3.3A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.64A","2itoA-3sxsA:30.8","2itoA-3sxsA:30.21"],["2ITO_A_IREA2020_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"LEU A 423;ALA A 443;MET A 464;THR A 489;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);PP2 A   1 (-3.3A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.75A","2itoA-3sxsA:30.8","2itoA-3sxsA:30.21"],["2ITO_A_IREA2020_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",6,"LEU A1951;ALA A1978;LYS A1980;MET A2001;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.74A","2itoA-3zbfA:26.1","2itoA-3zbfA:33.52"],["2ITO_A_IREA2020_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"ALA A 649;LYS A 651;GLU A 668;MET A 672;THR A 697;GLY A 703;LEU A 751","None","0.80A","2itoA-3zfxA:34.7","2itoA-3zfxA:36.09"],["2ITO_A_IREA2020_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;ALA A 104;LYS A 106;LEU A 152;GLY A 160;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 (-3.4A);VX6 A 500 (-3.3A);None;VX6 A 500 (-3.3A);VX6 A 500 (-4.6A)","0.72A","2itoA-4af3A:19.7","2itoA-4af3A:23.75"],["2ITO_A_IREA2020_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 840;ALA A 866;LYS A 868;GLU A 885;GLY A 922;LEU A1035","B49 A2000 (-3.7A);B49 A2000 (-3.5A);B49 A2000 (-3.0A);None;B49 A2000 ( 3.7A);B49 A2000 (-4.5A)","0.74A","2itoA-4agdA:29.9","2itoA-4agdA:30.02"],["2ITO_A_IREA2020_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"ALA A 121;LYS A 123;MET A 144;THR A 169;GLY A 175;LEU A 223","30K A1365 (-3.2A);30K A1365 (-3.8A);None;30K A1365 (-3.8A);30K A1365 (-3.5A);30K A1365 (-4.5A)","0.72A","2itoA-4aw5A:32.7","2itoA-4aw5A:33.03"],["2ITO_A_IREA2020_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"ALA A 233;LYS A 235;GLU A 248;LEU A 281;GLY A 289;ASP A 293;LEU A 343","TAK A1507 (-3.3A);TAK A1507 ( 4.5A);None;None;TAK A1507 (-3.5A);None;TAK A1507 (-4.7A)","0.92A","2itoA-4c02A:26.9","2itoA-4c02A:23.80"],["2ITO_A_IREA2020_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"ALA A 233;LYS A 235;GLU A 248;THR A 283;GLY A 289;ASP A 293;LEU A 343","TAK A1507 (-3.3A);TAK A1507 ( 4.5A);None;TAK A1507 (-3.6A);TAK A1507 (-3.5A);None;TAK A1507 (-4.7A)","0.91A","2itoA-4c02A:26.9","2itoA-4c02A:23.80"],["2ITO_A_IREA2020_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"LEU A 616;ALA A 653;LYS A 655;GLU A 672;MET A 676;THR A 701","None;DI1 A1000 (-3.6A);DI1 A1000 (-3.9A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.6A)","0.71A","2itoA-4ckrA:29.3","2itoA-4ckrA:32.87"],["2ITO_A_IREA2020_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",8,"LEU A 377;ALA A 400;LYS A 402;GLU A 420;MET A 424;LEU A 446;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;None;None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.65A","2itoA-4f4pA:32.5","2itoA-4f4pA:39.26"],["2ITO_A_IREA2020_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 377;ALA A 400;LYS A 402;LEU A 446;GLY A 454;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);None;ANP A 701 ( 4.2A);ANP A 701 (-4.5A)","0.43A","2itoA-4fl3A:29.7","2itoA-4fl3A:25.46"],["2ITO_A_IREA2020_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",8,"LEU A 855;ALA A 880;LYS A 882;GLU A 898;LEU A 927;GLY A 935;ASP A 939;LEU A 983","IZA A2001 (-3.7A);IZA A2001 (-3.4A);IZA A2001 ( 4.7A);None;None;IZA A2001 (-3.3A);None;IZA A2001 ( 4.7A)","0.80A","2itoA-4gl9A:30.9","2itoA-4gl9A:34.39"],["2ITO_A_IREA2020_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"LEU A 828;ALA A 853;LYS A 855;GLU A 871;LEU A 900;GLY A 908;LEU A 956","19S A1201 (-3.9A);19S A1201 (-3.3A);19S A1201 (-3.5A);None;None;19S A1201 ( 3.8A);19S A1201 (-4.5A)","0.91A","2itoA-4hviA:31.9","2itoA-4hviA:34.66"],["2ITO_A_IREA2020_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"LEU A 132;ALA A 156;LYS A 158;THR A 205;GLY A 211;ASP A 215;LEU A 259","None","0.63A","2itoA-4hzsA:29.3","2itoA-4hzsA:36.02"],["2ITO_A_IREA2020_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 132;ALA A 156;LYS A 158;THR A 205;GLY A 211;ASP A 215;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);None;1G0 A 401 (-4.6A)","0.77A","2itoA-4id7A:32.5","2itoA-4id7A:36.06"],["2ITO_A_IREA2020_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;ALA A 293;LYS A 295;GLY A 344;ASP A 348;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);0J9 A 601 ( 4.1A);None;0J9 A 601 (-4.5A)","0.50A","2itoA-4k11A:29.0","2itoA-4k11A:26.58"],["2ITO_A_IREA2020_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"LEU A 478;ALA A 506;LYS A 508;GLU A 525;MET A 529;GLY A 561;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-3.3A);ACP A 801 (-2.7A);ACP A 801 ( 4.8A);None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A)","0.71A","2itoA-4k33A:26.9","2itoA-4k33A:32.04"],["2ITO_A_IREA2020_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",6,"ALA A 434;LYS A 436;MET A 456;GLY A 487;ASP A 491;LEU A 533","B49 A 701 (-3.2A);None;None;B49 A 701 ( 3.7A);B49 A 701 ( 4.3A);B49 A 701 (-4.5A)","0.68A","2itoA-4ks8A:25.1","2itoA-4ks8A:26.14"],["2ITO_A_IREA2020_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"LEU A  33;ALA A  54;LYS A  56;MET A  74;GLY A 105;LEU A 153","GOL A 404 ( 3.6A);GOL A 404 ( 3.1A);GOL A 403 ( 4.6A);None;GOL A 404 (-3.6A);GOL A 403 ( 4.4A)","0.71A","2itoA-4lg4A:17.6","2itoA-4lg4A:28.75"],["2ITO_A_IREA2020_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"LEU A 273;ALA A 293;LYS A 295;GLU A 310;MET A 314;GLY A 344;ASP A 348","VGG A 601 (-3.2A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.3A);VGG A 601 ( 3.6A);VGG A 601 ( 3.2A);None","0.90A","2itoA-4lggA:29.6","2itoA-4lggA:32.73"],["2ITO_A_IREA2020_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"LEU A 273;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;LEU A 393","VGG A 601 (-3.2A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 3.6A);VGG A 601 ( 3.2A);None;VGG A 601 (-4.5A)","0.61A","2itoA-4lggA:29.6","2itoA-4lggA:32.73"],["2ITO_A_IREA2020_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"ALA A  49;LYS A  51;LEU A  93;THR A  95;GLY A 101;LEU A 150","ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;ANP A 401 (-3.8A);None;ANP A 401 (-4.8A)","0.69A","2itoA-4m69A:24.0","2itoA-4m69A:25.28"],["2ITO_A_IREA2020_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;ALA A  67;LYS A  69;GLU A  85;LEU A 121;THR A 123;GLY A 128;LEU A 180","SIN A 401 ( 3.9A);SIN A 401 ( 3.7A);None;None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.68A","2itoA-4o38A:21.0","2itoA-4o38A:22.13"],["2ITO_A_IREA2020_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;ALA A  67;LYS A  69;GLU A  85;MET A  89;LEU A 121;THR A 123;GLY A 128","SIN A 401 ( 3.9A);SIN A 401 ( 3.7A);None;None;None;None;None;SIN A 401 (-3.5A)","0.77A","2itoA-4o38A:21.0","2itoA-4o38A:22.13"],["2ITO_A_IREA2020_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;ALA A 928;GLU A 947;LEU A 976;GLY A 984;ASP A 988;LEU A1030","2TT A1202 (-3.5A);2TT A1202 ( 3.9A);None;None;2TT A1202 (-3.4A);None;2TT A1202 (-4.4A)","0.93A","2itoA-4oliA:29.5","2itoA-4oliA:20.36"],["2ITO_A_IREA2020_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 818","P30 A1001 (-3.8A);P30 A1001 (-3.4A);P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.70A","2itoA-4rt7A:24.7","2itoA-4rt7A:28.76"],["2ITO_A_IREA2020_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;ALA A 642;LYS A 644;GLU A 661;LEU A 689;GLY A 697","P30 A1001 (-3.8A);P30 A1001 (-3.4A);P30 A1001 (-3.4A);P30 A1001 (-3.6A);None;P30 A1001 (-3.4A)","0.73A","2itoA-4rt7A:24.7","2itoA-4rt7A:28.76"],["2ITO_A_IREA2020_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"LEU A  14;ALA A  35;LYS A  37;GLU A  52;MET A  56;GLY A  87;ASP A  91;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-2.9A);None;None;None;ACP A1264 (-3.5A);None;ACP A1264 ( 4.8A)","0.78A","2itoA-4ueuA:32.3","2itoA-4ueuA:35.54"],["2ITO_A_IREA2020_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"LEU A  14;ALA A  35;LYS A  37;MET A  56;THR A  81;GLY A  87;ASP A  91;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-2.9A);None;None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);None;ACP A1264 ( 4.8A)","0.74A","2itoA-4ueuA:32.3","2itoA-4ueuA:35.54"],["2ITO_A_IREA2020_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;ALA A 214;LYS A 216;GLU A 235;LEU A 262;GLY A 270;LEU A 321","ANW A 601 ( 4.0A);ANW A 601 (-3.4A);None;None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.68A","2itoA-4wboA:24.3","2itoA-4wboA:20.37"],["2ITO_A_IREA2020_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.67A","2itoA-4xeyB:26.8","2itoA-4xeyB:28.51"],["2ITO_A_IREA2020_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",7,"LEU B 267;ALA B 288;LYS B 290;THR B 334;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.63A","2itoA-4xeyB:26.8","2itoA-4xeyB:28.51"],["2ITO_A_IREA2020_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;ALA A 642;GLU A 661;LEU A 689;GLY A 697;LEU A 818","P30 A1001 (-4.0A);P30 A1001 (-3.5A);P30 A1001 (-3.1A);None;P30 A1001 (-3.5A);P30 A1001 (-4.3A)","0.63A","2itoA-4xufA:24.1","2itoA-4xufA:32.96"],["2ITO_A_IREA2020_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;ALA A 214;LYS A 216;GLU A 235;LEU A 262;LEU A 319","AN2 A 601 ( 4.2A);AN2 A 601 (-3.6A);AN2 A 601 ( 3.9A);None;None;None","0.68A","2itoA-4yhjA:22.7","2itoA-4yhjA:21.88"],["2ITO_A_IREA2020_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",8,"LEU A  34;ALA A  55;LYS A  57;GLU A  76;LEU A 103;THR A 105;GLY A 111;LEU A 158","ADP A 506 ( 3.8A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);None;None;ADP A 506 ( 4.6A);None;ADP A 506 (-4.7A)","1.00A","2itoA-4ysjA:24.4","2itoA-4ysjA:22.54"],["2ITO_A_IREA2020_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"LEU A  34;ALA A  55;LYS A  57;THR A 105;GLY A 111;ASP A 115;LEU A 158","ADP A 506 ( 3.8A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);ADP A 506 ( 4.6A);None;None;ADP A 506 (-4.7A)","1.00A","2itoA-4ysjA:24.4","2itoA-4ysjA:22.54"],["2ITO_A_IREA2020_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"LEU A 484;ALA A 512;LYS A 514;GLU A 531;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-3.6A);38O A1769 ( 3.1A);EDO A1766 (-4.1A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.67A","2itoA-5a46A:30.9","2itoA-5a46A:31.20"],["2ITO_A_IREA2020_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"ALA A  44;LYS A  46;GLU A  63;LEU A  90;GLY A  98;LEU A 145","51W A 401 (-3.4A);GOL A 404 ( 3.1A);None;None;51W A 401 (-3.7A);51W A 401 (-4.5A)","0.73A","2itoA-5ci7A:19.1","2itoA-5ci7A:26.38"],["2ITO_A_IREA2020_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"ALA A 275;LYS A 277;GLU A 290;LEU A 323;THR A 325;GLY A 331;LEU A 386","STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 ( 3.8A);None;STU A 601 ( 3.7A);STU A 601 (-3.5A);STU A 601 (-3.9A)","0.52A","2itoA-5e8yA:25.9","2itoA-5e8yA:25.42"],["2ITO_A_IREA2020_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",6,"LEU A  99;ALA A 120;LYS A 122;LEU A 168;GLY A 176;LEU A 223","5U5 A 401 (-3.8A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);None;5U5 A 401 (-3.4A);5U5 A 401 (-4.7A)","0.53A","2itoA-5eykA:24.8","2itoA-5eykA:23.89"],["2ITO_A_IREA2020_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",8,"LEU A 903;ALA A 928;LYS A 930;GLU A 947;LEU A 976;GLY A 984;ASP A 988;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 (-3.5A);None;None;None;5U3 A1200 (-3.2A);None;5U3 A1200 (-4.4A)","0.87A","2itoA-5f1zA:29.8","2itoA-5f1zA:30.95"],["2ITO_A_IREA2020_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",6,"LEU A 730;ALA A 756;LYS A 758;LEU A 802;GLY A 810;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);None;PTR A 809 (-2.4A);PP1 A2012 (-4.6A)","0.47A","2itoA-5fm2A:33.4","2itoA-5fm2A:30.36"],["2ITO_A_IREA2020_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"LEU A 599;ALA A 625;LYS A 627;GLU A 644;MET A 648;THR A 674","748 A1001 (-3.8A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 (-3.2A)","0.75A","2itoA-5grnA:24.9","2itoA-5grnA:30.21"],["2ITO_A_IREA2020_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"LEU A 599;ALA A 625;LYS A 627;GLU A 644;THR A 674;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.3A);748 A1001 (-3.2A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.70A","2itoA-5grnA:24.9","2itoA-5grnA:30.21"],["2ITO_A_IREA2020_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"LEU A  20;ALA A  41;LYS A  43;GLU A  61;LEU A  88;GLY A  96;LEU A 143","ADP A 301 ( 4.0A);ADP A 301 (-3.5A);ADP A 301 (-2.7A);None;None;None;ADP A 301 (-4.7A)","0.87A","2itoA-5hu3A:24.9","2itoA-5hu3A:23.78"],["2ITO_A_IREA2020_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",10,"LEU A 718;ALA A 743;LYS A 745;GLU A 762;MET A 766;LEU A 788;GLY A 796;ASP A 800;LEU A 844;THR A 854","6HJ A1101 ( 4.6A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);6HJ A1101 ( 4.2A);6HJ A1101 ( 4.1A);6HJ A1101 ( 4.6A);6HJ A1101 ( 4.5A);6HJ A1101 ( 4.1A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A)","0.54A","2itoA-5j9zA:44.0","2itoA-5j9zA:99.38"],["2ITO_A_IREA2020_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",7,"ALA A 417;LYS A 419;GLU A 436;LEU A 463;GLY A 471;ASP A 475;LEU A 518","GUI A 701 ( 3.9A);GUI A 701 (-3.1A);None;None;GUI A 701 (-3.6A);GUI A 701 (-4.1A);GUI A 701 (-4.4A)","0.73A","2itoA-5jznA:24.0","2itoA-5jznA:25.80"],["2ITO_A_IREA2020_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",6,"SER A  42;ALA A  60;LEU A 108;GLY A 116;LEU A 163;THR A 173","STU A 901 ( 4.8A);STU A 901 (-3.3A);None;STU A 901 (-3.5A);STU A 901 (-4.5A);STU A 901 (-3.5A)","0.67A","2itoA-5lohA:20.3","2itoA-5lohA:24.86"],["2ITO_A_IREA2020_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"ALA A 909;LYS A 911;GLU A 927;LEU A 954;GLY A 962;LEU A1016","ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A)","0.51A","2itoA-5lpyA:24.8","2itoA-5lpyA:27.59"],["2ITO_A_IREA2020_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"ALA A 909;LYS A 911;GLU A 927;LEU A 954;GLY A 962;ASP A 966;LEU A1016","ADP A1200 (-3.5A);ADP A1200 ( 4.3A);None;None;ADP A1200 ( 4.0A);ADP A1200 (-4.2A);ADP A1200 (-4.7A)","0.69A","2itoA-5lpzA:24.7","2itoA-5lpzA:26.48"],["2ITO_A_IREA2020_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"ALA A 119;LYS A 121;GLU A 140;MET A 144;GLY A 175;LEU A 221","None","0.73A","2itoA-5u7qA:21.4","2itoA-5u7qA:24.04"],["2ITO_A_IREA2020_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",7,"LEU A  24;SER A  25;ALA A  45;LYS A  47;THR A  95;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);None;9WS A 401 (-3.3A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.76A","2itoA-5w5jA:23.2","2itoA-5w5jA:28.81"],["2ITO_A_IREA2020_1","5wnm","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 4","no annotation",6,"ALA A  49;GLU A  69;MET A  73;LEU A  94;GLY A 102;LEU A 150","VX6 A 402 (-3.2A);VX6 A 402 (-4.4A);None;None;VX6 A 402 (-3.5A);VX6 A 402 (-4.4A)","0.71A","2itoA-5wnmA:28.5","2itoA-5wnmA:13.64"],["2ITO_A_IREA2020_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"LEU A 891;ALA A 917;LYS A 919;THR A 963;GLY A 969;LEU A1017;THR A1027","ANP A1201 (-4.1A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);ANP A1201 (-3.9A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A);ANP A1201 ( 4.9A)","0.77A","2itoA-5wnoA:31.4","2itoA-5wnoA:12.74"],["2ITO_A_IREA2020_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;ALA A 906;LYS A 908;GLU A 925;LEU A 954;GLY A 962;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-3.4A);ADP A1201 (-2.8A);None;None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.79A","2itoA-6c7yA:31.1","2itoA-6c7yA:14.24"],["2ITO_A_IREA2020_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",6,"LEU A 730;ALA A 756;GLU A 775;LEU A 802;GLY A 810;LEU A 881","ADN A1104 ( 4.0A);ADN A1104 (-3.4A);None;None;ADN A1104 ( 3.8A);ADN A1104 (-4.3A)","0.69A","2itoA-6fekA:32.2","2itoA-6fekA:14.29"]]